FDCC
EVH icon

Foster Dykema Cabot & Co’s Evolent Health EVH Stock Holding History

Foster Dykema Cabot & Co’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-119
Closed -$4K – 347
2023
Q2 		$4K Buy
+119
New +$3.85K ﹤0.01% 318

Other funds holding EVH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Foster Dykema Cabot & Co's EVH Position: Q3 2023 in Review

Foster Dykema Cabot & Co sold out of Evolent Health (EVH) in Q3 2023, closing a stake of 119 shares — an estimated $4K sold.

Foster Dykema Cabot & Co first reported a position in EVH in Q2 2023 and held it in 1 quarter. The position peaked at $4K in Q2 2023. 203 funds tracked by Wall St. Rank hold EVH as of Q3 2023.

  • Foster Dykema Cabot & Co reported no remaining Evolent Health position as of Q3 2023 after selling out during the quarter.
  • Foster Dykema Cabot & Co sold 119 Evolent Health shares in Q3 2023, an estimated $4K.
  • Foster Dykema Cabot & Co first reported a position in Evolent Health in Q2 2023 and held it in 1 quarter.
  • Foster Dykema Cabot & Co's Evolent Health position peaked at $4K in Q2 2023.
  • 203 funds tracked by Wall St. Rank held Evolent Health as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.